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ABSTRACT 
 
Human immunodeficiency virus type 1 (HIV-1), a causative agent of 
acquired immunodeficiency syndrome (AIDS), and Mycobacterium tuberculosis (Mtb), 
a causative agent of tuberculosis (TB), are among the leading causes of death from 
infectious disease worldwide. Interplay between HIV-1 and Mtb leads to the 
detrimental dysregulation of immune system mechanisms, which provides the 
conditions facilitating progression of the disease in co-infected individuals. 
In order to investigate the impact of Mtb and HIV-1 on innate immune 
responses we set up in vitro infection models comprising human monocyte-derived 
macrophages (Mφs) and dendritic cells (DCs). Firstly, we examined the influence of 
mycobacterial cell wall-derived glycolipids on the function of DCs. We found that 
two cell wall components, ManLAM and PIM, modulate DC function in an opposite 
manner, where ManLAM stimulates the production of pro-inflammatory cytokines, 
while PIM inhibits cytokine production triggered by activated DCs. Next, we 
analyzed several clinical Mtb isolates causing a large TB outbreak in Sweden. We 
found that the clinical isolates are characterized by the ability to trigger increased 
production of TNF from in vitro infected Mφs, above that triggered by the Mtb 
reference strain. Knowing that different mycobacterial glycolipids may differently 
impact DC and having several Mtb clinical isolates characterized, we investigated 
the effects of ongoing Mtb infection on the function of bystander DCs. Here we 
demonstrated that mycobacteria-infected Mφs create a pro-inflammatory milieu in 
which DCs undergo partial maturation, produce pro-inflammatory cytokines and 
additionally increase their ability to mediate HIV-1 trans-infection of T cells. Finally, 
we investigated mechanisms behind the altered cytokine response to Mtb during 
concurrent HIV-1 infection. We observed that the levels of cytokines released from 
Mtb-infected Mφs are lower after HIV-1 pre-exposure than those observed from 
singly Mtb-infected Mφs. Next, we measured levels of miR-146a, a microRNA 
known to inhibit signaling cascades leading to production of pro-inflammatory 
cytokines. We found that miR-146a was up-regulated upon Mtb infection and also 
after HIV-1 exposure, suggesting that HIV-triggered miR-146a expression may be 
responsible for cross-tolerance of Mφs to following Mtb infection. Furthermore, we 
showed that exposure to the HIV-1 envelope glycoprotein gp120 is sufficient to up-
regulate miR-146a, which in turn is paralleled by down-modulated responsiveness 
of Mφs to a secondary stimulus, i.e. the Mtb glycolipid ManLAM. 
In conclusion, this thesis highlights that several innate immune mechanisms 
are modulated by either HIV-1 or Mtb, which may hamper adequate immune 
responses against the two pathogens. These studies also suggest that the effects may 
be triggered in a bystander manner, where impacted cells are not infected and may 
be even localized distantly from the site of infection. 
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1 INTRODUCTION 
 
 
 
1.1 IMMUNITY TO INFECTIONS 
 
 
The role of the immune system is to protect the organism from the invasion 
of broadly defined threats, including pathogens but also dangers derived from 
within the organism that are the results of malfunctions, including malignant 
transformation. 
The immune system is a network of organs, tissues, cells and soluble factors 
working together to maintain homeostasis of the body and to ensure a safe 
environment for other organs to work and perform their functions. Skin and mucosa, 
which constitute the mechanical barrier, provide a physical protection of the 
organism from potentially hazardous objects from outside. This barrier is often 
penetrated by pathogens and then the main task of the immune system is to 
recognize the threat as quickly as possible and to signal its presence to other 
components of the immunity network in order to trigger an adequate response. This 
is possible owing to the different pattern recognition receptors (PRRs) expressed by 
cells of the immune system and also by other cells [1]. Pathogens and infected cells 
can be directly recognized or taken up by specialized cells, called antigen presenting 
cells (APCs), including phagocytes, which process antigens (Ags) and present them 
for the recognition by specific receptors on the T and B cells. Such recognition of 
danger signal is accompanied by the release of panels of cytokines and chemokines, 
signaling molecules that help to recruit more cells to the site of infection and to 
mobilize additional defense mechanisms [1]. 
Generally, the immune system is divided into two branches: innate and 
adaptive immunity. Innate immunity includes evolutionary older mechanisms 
acting fast but with limited specificity. Cells of innate immunity include dendritic 
cells (DCs), macrophages (Mφs), granulocytes, NK cells, NKT cells and γδT cells. 
Adaptive immunity on the other hand is more specific but requires time to develop 
after recognition of the threat. T cells and B cells belong to this group and they need 
instructions from APCs in order to function properly [1]. 
Thus, the first goal of the immune system is to recognize, act and eliminate 
the threat. Another, equally important aim is to remember the primary insult. After 
the first encounter of the pathogen the immune system, especially the adaptive 
immune system, generates a memory, which upon the next invasion of the same 
danger is mobilized much more quickly and allows the organism to eliminate the 
threat much faster and without causing too extensive damage. The memory of the 
immune system is employed in vaccination, where a small amount of inactivated 
pathogens, subunits or attenuated pathogens are given to the organism. This causes 
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a mobilization of the immune response, allowing for developing a memory, which 
upon contact with the real pathogens ensures a quick and effective elimination of the 
microorganism without causing disease. 
Sometimes, however, the immune response is triggered by a minor cause, the 
response is too extensive relative to the threat or is directed against host antigens, i.e. 
self-antigens. This may lead to immunopathology and autoimmunity, as seen for 
instance in rheumatoid arthritis, autoimmune thyroid disorders and many more 
conditions together called diseases from autoaggression.  
 
 
 
1.1.1 Innate immunity 
 
 
Early concepts in immunology described innate immunity as a non-specific 
branch of the immune system. However, discovery of Toll-like receptors (TLRs) and 
other families of PRRs demonstrated that in fact innate immunity receptors 
specifically recognize pathogen-associated molecular patterns (PAMPs) [2]. The 
recognition of PAMPs by TLRs occurs in the plasma membrane, endosomes, 
lysosomes and endolysosomes [3]. In addition, cell type–specific TLR repertoires and 
cell type-specific signaling pathways activated by specific TLR define their 
immunological properties [2, 3]. Upon binding of the ligand, adaptor molecules are 
recruited to cytoplasmic domains of TLRs which results in triggering of a 
downstream signaling cascade leading to production of pro-inflammatory cytokines 
and chemokines [3]. 
Out of ten functional TLRs known in humans several are involved in 
recognition of PAMPs derived from Mtb or HIV-1. For instance, TLR2, 4 and 9 are 
known to be engaged in recognition of mycobacteria-derived ligands [4]. 
Modulation of granuloma progression and cytokine production during Mtb infection 
has been found to be related to the recognition of the mycobacterial GC-rich genome 
by TLR9 [4-6]. The mycobacterial cell wall comprises a variety of lipopeptides and 
liposaccharides that stimulate TLR2 [4, 7], whereas TLR4 is activated by Mtb heat 
shock proteins [8]. HIV-derived PAMPs are also recognized by TLRs. The HIV 
genomic single-stranded RNA is able to activate TLR7/8 [9]; double-stranded DNA, 
which is formed as an intermediate during the HIV replication cycle, may trigger 
TLR9; whereas double-stranded RNA is recognized by TLR3 [10, 11]. 
Another important group of PRRs are C-type lectin receptors (CLRs), 
calcium-dependent carbohydrate-binding proteins. This group includes among 
others: dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN), mannose receptor (MR), langerin and dectin 1 and 2 [12]. CLRs 
are able to trigger a pathogen specific response either by modulating TLR signaling 
or by direct modulation of gene expression [12]. Both MR and DC-SIGN may bind 
  
 
3 
 
 
highly mannosylated molecules, hence a mycobacterial cell wall component, 
mannose-capped lipoarabinomannan (ManLAM), and the viral envelope 
glycoprotein gp120 of HIV-1 strongly interact with these receptors [12-14]. 
 
 
1.1.1.1 Dendritic cells 
 
Dendritic cells are professional APCs with the unique ability to stimulate 
naïve T cells [1]. They comprise a sparsely distributed, heterogeneous population 
displaying differences in origins, localization, migratory pathways and function [15]. 
DCs are the only immune cells that can have either myeloid or lymphoid origin and 
are found in the blood, skin, mucosa and across many organs in the body [15, 16]. 
DCs are perceived as immune system sentinels, which sample their environment and 
upon recognition of a danger signal trigger innate immune responses and initiate 
adaptive immune responses. Therefore, they are equipped with a large panel of 
PRRs (including C-type lectins) which allows them to quickly recognize and react to 
the presence of pathogens and their components [17]. 
Generally, upon capture of Ag, DCs undergo a maturation process with 
surface up-regulation of MHC class II and other molecules engaged in Ag 
presentation. In addition they migrate from their primary location to the lymph 
nodes and secrete a spectrum of cytokines providing appropriate signals to interact 
with T cells and elicit an effective immune response. DCs initiate different types of 
immune responses depending on their origin, location and the type of the signal 
triggering their activation [17]. 
There are two main subsets of DCs: myeloid DCs (mDCs) and plasmacytoid 
DCs (pDCs). Blood mDCs and pDCs represent 0.5-2% of the total peripheral blood 
mononuclear cell (PBMC) population [16]. They differ in expression of surface 
markers, e.g. mDCs express CD11c whereas expression of CD123 and lack of CD11c 
is specific for pDCs [18, 19]. In addition, mDCs are known to produce large amounts 
of IL-12, while pDCs secrete important antiviral cytokines, i.e. type I interferons 
(IFN) [16, 20, 21]. The common feature of DCs is their ability to prime naïve T cells 
following processing and presentation of Ags. 
Human mucosa is well populated by distinct DCs in order to constantly 
survey surfaces exposed to potential pathogen invasion and to induce an 
inflammatory response when needed [22]. For instance, mucosal tissue of the 
reproductive tract includes Langerhans cells (LCs), submucosal mDCs and upon 
infection it is also rapidly infiltrated by pDCs [22]. Vaginal, submucosal DCs have 
been demonstrated to migrate to the draining lymph nodes and initiate an anti-viral 
cellular response upon Herpes simplex type 2 infection [23]. Moreover, another study 
in a similar model has shown that infiltrated pDCs provide large concentrations of 
anti-viral cytokine IFN-α [24]. Analogous observations have been made for pDCs 
  
 
4 
 
 
attracted to the lymph nodes during acute infection with simian immunodeficiency 
virus (SIV) in Rhesus macaques [25]. 
LCs are found in the epidermis and mucosal epithelia [26]. They are typical 
APCs with high capacity to capture, process and present Ags to T cells. LCs are the 
only known human cells expressing langerin (CD207) that is an important PRR with 
specificity for mannose, fucose and N-acetyl-glucosamine monosaccharides [27]. 
This specificity is shared with DC-SIGN that also interacts with mannose and fucose 
structures, yet it is not expressed on LCs [26]. Ligands bound to langerin may be 
internalized and directed to processing via the non-classical Ag presentation 
pathway. It has also been speculated that langerin, similarly to DC-SIGN, upon 
binding of the ligand might trigger a signaling cascade modulating the cytokine 
response of LCs [26]. 
Follicular DCs are a different type of DCs. They are stromal cells of 
mesenchymal origin, thus not derived from the hematopoietic stem cells, and are not 
able to process Ags and present them in the context of MHC class II [28]. Follicular 
DCs reside in the B cell follicles and germinal centers of the peripheral lymphoid 
tissues where they support B cell survival and proliferation [28]. They retain the 
opsonized Ag on their surface which has been shown to be a more effective way of B 
cell stimulation than by soluble Ags [29]. 
DCs are scarce in the blood and therefore their isolation for in vitro studies is 
difficult. Instead, a widely used, laboratory-adapted model comprises monocyte 
derived DCs (moDCs). They originate from monocytes isolated from the blood 
which are differentiated to DCs in the presence of granulocyte/macrophage colony 
stimulating factor (GM-CSF) and IL-4 [30]. Such moDCs resemble mDCs by 
expressing CD11c, DC-SIGN and MR, MHC class I and II and co-stimulatory 
molecules, CD80 and CD86. They are also able to phagocytose, process and present 
Ags, secrete a panel of cytokines in response to stimulation and acquire a phenotype 
of mature DCs. Although they are a feasible model they do not fully mimic DCs 
found in vivo. 
 
 
1.1.1.2 Macrophages 
 
Macrophages (Mφs) are APCs residing in tissues and characterized by high 
phagocytic activity. They originate from the myeloid hematopoietic branch and 
develop from monocytes recruited to the tissue from the blood [31]. Monocytes, 
constituting 5-10% of blood leukocytes, circulate in the peripheral blood for several 
days and are able to migrate out to tissue to give rise to a variety of Mφs, but also to 
some DCs and osteoclasts [15, 32, 33]. Several groups, however, observed that a local 
proliferation of the Mφ lineage is possible as well [34-36]. 
Mφs play an important role in the maintenance of tissue homeostasis, 
through the clearance of apoptotic cells, and remodeling and repair of tissues [31]. 
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They actively participate in sampling of their environment, recognizing pathogens 
and infected cells and presenting Ags to T cells. Mφs are capable of not only 
receptor-mediated endocytosis but also internalization of particulate material via 
membrane ruffling and folding mechanisms [37]. The Mφ population is 
heterogeneous depending on the tissue they reside in and on the role they play in a 
specific location [32]. The lung Mφ population, for instance, includes alveolar, 
pleural, interstitial and intravascular Mφs expressing a wide spectrum of PRRs and 
other scavenger receptors in order to recognize and react to the presence of danger 
signals [38]. The respiratory tract is repeatedly exposed to inhaled microorganisms 
therefore strong and efficient defense mechanisms are so crucial there [36]. Binding 
of PAMP to a specific receptor triggers a cascade of signals in Mφs leading to their 
activation. It includes release of a panel of cytokines and chemokines attracting other 
cells to the site of infection, use of lysosomal enzymes and activation of killing 
mechanisms involving the release of toxic oxygen and nitrogen species [36, 37]. 
 
 
 
1.1.2 Interactions between innate and adaptive immunity 
 
 
Cells of the innate immunity co-operate closely with cells of the adaptive 
immunity. Antigen presentation by DCs and Mφs is critical to successful 
development of both cell-mediated and humoral immunity [37]. Fast recognition of 
pathogen followed by phagocytosis, processing and presentation of Ags to T and B 
cells is accompanied by release of the appropriate spectrum of cytokines and 
chemokines. All these requirements must be fulfilled in order to initiate an effective 
immune response. 
A crucial link between innate and adaptive immunity is made when APCs 
present Ag to T cells in order to initiate their activation leading to development of 
specific mechanisms directed against invading pathogen or other threats. Interaction 
between APCs and T cells requires close contact, where the T cell, using its T cell 
receptor (TCR) recognizes Ag presented by APC [1]. Yet, such recognition alone is 
not enough to initiate T cell activation. A second signal is needed, which is provided 
by an interaction between co-stimulatory molecules on the surface of the APC (CD80 
and CD86) and the T cell (CD28). Up-regulation of co-stimulatory molecules is 
observed on DCs during their maturation following recognition of the pathogen, 
which strengthens their ability to activate T cells. To fully activate the T cell the APC 
needs to supply a so-called “third signal”. This signal comprises a panel of pro-
inflammatory cytokines that are delivered to T cells in order to trigger additional 
pathways leading to activation. A tight controlling mechanism behind T cell 
activation is essential to avoid accidental triggering and persistent activation, which 
could lead to unnecessary immune system mobilization and immunopathology. 
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The interface between the APC and the T cell, created during the priming 
process, is called the immunological synapse, after neurological synapse that also 
requires a close contact between two cells. Such proximity of two immune cells is 
sometimes used by pathogens for efficient spread between cells. An example of such 
a pathogen is HIV, which makes use of the immunological synapse formation to 
spread from DC to T cell [39, 40]. 
B cells are another important component of the adaptive immune response. 
They are responsible for the humoral immunity, which includes the production and 
release of antibodies (Abs). B cell activation and differentiation into Ab-secreting 
plasma cells is driven by Ag recognition and most often requires contact with T 
helper cells [1]. The immune system makes use of Abs in several ways. Some Abs 
possess a neutralizing capability; that means that pathogens or their components, 
including toxins, may be either opsonized or sterically hindered by Abs and thus 
prevented from reaching or infecting target cells. There are also Abs that instead 
may facilitate uptake of the pathogens by phagocyting cells, which leads to pathogen 
degradation and presentation of its Ags. On the other hand, some pathogens have 
developed mechanisms that use this system to infect the cells. Additionally, 
pathogens opsonized by Abs can trigger a cascade of complement activation that 
leads to microorganism degradation by forming pores in their membranes [1]. 
 
 
 
1.1.3 microRNA 
 
 
1.1.3.1 General background and biogenesis 
 
MicroRNA (miR) is a class of short, non-coding RNAs first described in 
Caenorhabditis elegans in 1993 [41]. Since then miRs have been extensively studied and 
their role in controlling many processes, including cell development, proliferation, 
differentiation, apoptosis, cancerogenesis and immune system regulation, has been 
widely appreciated. 
miRs are about 22 nucleotide-long RNA molecules that can post-
transcriptionally down-regulate expression of target messenger RNAs (mRNAs) by 
imperfect binding to the 3’-untranslated regions of such mRNAs [42]. There are 
nearly one thousand different human miRs identified to date [43]. Some of them 
regulate specific individual targets, while others can function as master regulators of 
a specific process [44]. Some miRs can potentially regulate the expression levels of 
several hundred distinct mRNAs simultaneously, and many types of miRs regulate 
their targets cooperatively [44, 45]. Therefore miRs emerged as important regulators 
of gene expression being responsible for controlling expression of more than 60% of 
protein coding genes [44]. 
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miRs are encoded within the introns and exons of longer primary transcripts, 
including protein-coding transcripts [46] and are most often transcribed from the 
genome by RNA polymerase II giving rise to transcripts which length can extend 
even over 1 kb fragments forming hairpin structures, primary-miRs (Figure 1) [47, 
48]. Primary-miRs are further processed in the nucleus by the enzyme complex 
Drosha and are cleaved to about 70 nucleotide-long precursor-miRs and thereafter 
exported to the cytoplasm by the exportin 5 [48]. In the cytoplasm, immature miRs 
are further cleaved by the enzyme DICER that cleaves the terminal loop structure to 
form double-stranded miR [47, 48]. After dissociation, single-stranded, mature miR 
together with Ago protein, forms RISC (RNA-induced silencing complex) that can 
bind to the target mRNA, leading to inhibition of translation initiation or to the 
mRNA degradation [44]. 
 
 
 
Figure 1. Schematic representation of canonical miR biogenesis. pri-miRNA – primary miR, pre-miRNA 
– precursor-miR. Adapted with changes from [47]. 
 
 
1.1.3.2 Role of miRs in controlling immune system 
 
miRs have been demonstrated to be crucial for regulation of the immune 
response. They are involved in fine-tuning of the immune system assuring its well-
orchestrated status since too strong or unnecessarily prolonged induction of the 
immune response can be harmful to the organism. Such quantitative regulation of 
gene expression has been implicated in controlling both innate and adaptive 
immune system branches on the several distinct levels, including immune cell 
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survival and differentiation as well as modulation of signaling downstream from 
immune receptors [49, 50]. 
 
 
1.1.3.2.1 miR-146a 
 
miR-146a is a widely studied micro-RNA with diverse roles in cancer and 
immune system regulation [51]. miR-146a is expressed in response to a variety of 
microbial compounds and pro-inflammatory cytokines, being an NFκB-dependent 
gene [52]. TRAF6 and IRAK1 were found among the targets of miR-146a thus 
suggesting an impact on the signaling cascade downstream from TLRs and creating 
a negative feedback loop to activation of TLRs [52]. Indeed, expression of miR-146a 
has been correlated with LPS stimulation and found to be responsible for endotoxin 
self-tolerance [53, 54] and cross-tolerance to other TLR ligands [55]. miR-146a has 
also been implicated in the development of intestinal tolerance to microbiota in 
neonates, by regulation of cell survival, differentiation and establishment of mucosal 
homeostasis [56]. 
It has been observed that miR-146a is differentially expressed in DC subsets – 
with higher expression in Langerhans cells as compared with interstitial DCs. In 
addition, levels of this miR have been associated with DC cytokine production but 
not maturation state, and inversely correlated with responsiveness of cells to TLR2 
signaling [57]. miR-146a has also been described as a negative regulator of IL-12 
production in DCs [58] and could be induced by IL-10 in murine bone marrow-
derived Mφs [59]. miR-146a promotes development of Mφs from the hematopoietic 
stem cells and its loss leads to myeloproliferative disorders [60, 61]. Of note, 
malfunctioning of miR-146a-based negative feedback loops were observed in Mφs 
isolated from aged mice [62]. Such Mφs displayed abnormally high levels of        
miR-146a and impaired responsiveness to LPS and pro-inflammatory cytokines [62]. 
Furthermore, miR-146a has been demonstrated to play a role in adaptive immunity. 
It was shown to modulate Treg-mediated regulation of Th1 response [63] and to be 
induced in human [64] and murine [65] T cells upon T cell receptor stimulation. 
Recently it has been demonstrated that the expression of miR-146a in 
mononuclear cells isolated from circulation or pleural fluid from TB patients was 
decreased and accompanied by augmented levels of IL-6 and IL-1β [66]. 
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1.2 MYCOBACTERIAL INFECTIONS 
 
 
 
1.2.1 Tuberculosis 
 
 
Tuberculosis (TB) is one of the oldest human diseases and its etiology and 
infectious character was described already in 1882 by Robert Koch [67]. In spite of 
many advances in understanding its pathogenesis made in past years TB still 
remains one of the leading cause of death from the infectious disease worldwide [68, 
69]. WHO estimated that in 2010 there were 8.8 million TB cases worldwide and     
1.5 million deaths from TB, including TB among HIV-positive persons [68]. The risk 
of developing active TB among Mtb-infected but generally healthy people is 
estimated to be about 10% during lifetime [70, 71]. In the majority of infected 
individuals Mtb infection remains latent without giving rise to symptoms of active 
disease for long periods of time. 
TB is an airborne disease and transmission occurs from individuals with 
developed active pulmonary TB. In such patients TB lesions observed on lung X-rays 
are the results of lung tissue necrosis and cavity formation [69]. Upon rapture of 
such cavities and release to adjacent airways, the pathogen is carried by small 
aerosol droplets that are expelled by coughing, and when inhaled, can reach the lung 
of another individual [69]. It has been estimated that even single bacterium can give 
rise to the lung infection [72]. 
Cough is the most common symptom of pulmonary TB, and other symptoms 
comprise weight loss, lack of appetite, fever, malaise, and night sweats [71]. Among 
diagnostic tools available for TB is a tuberculin skin test, that is now being replaced 
by the blood-based tests assessing release of IFN-γ from Mtb-specific T cells [73]. 
Radiographic chest examination is also widely used to diagnose active TB and 
allows the doctors to assess the potential lung abnormalities related to TB lesions 
[71]. Laboratory diagnostic tools for identification of Mtb comprise direct detection 
of acid-fast bacilli by sputum smear microscopy, culture of mycobacteria isolated 
from patients’ samples or identification of specific mycobacterial strains by 
molecular tests based on analysis of bacterial DNA [68, 74]. 
The mortality rate of non-treated TB is high. Studies from pre-chemotherapy 
era on smear-positive, HIV-negative population with pulmonary TB showed that 
almost 70% of those patients died within 10 years [75]. Nowadays, available therapy 
allows for control the disease fairy well. As estimated by WHO, in 2009 87% of new 
cases of TB were successfully treated but multi-drug resistant and extensively drug 
resistant TB emerged as important problems in fighting TB [68].  
  
 
10 
 
 
While the lung is the most common location of TB, extrapulmonary TB is 
diagnosed in 15-20% of immunocompetent individuals with lymph nodes, pleura 
and abdomen being the most often affected [71, 76]. 
 
 
1.2.1.1 Primary Mtb infection and latency 
 
The primary Mtb infection starts when inhaled bacilli are taken up by 
phagocytic cells residing in lung alveoli. Even though Mφs are the main target cells 
for Mtb, DCs are also infected at the first stage of disease [77]. They get activated and 
migrate from the site of infection to the draining lymph nodes, where they present 
Mtb Ags to T cells. Yet, it has been observed that the entire process is delayed during 
Mtb infection and initiated not earlier than two weeks post-infection [78-80]. 
When the Mtb-infected cells reach lung tissue additional cells are recruited as 
a result of the initiated inflammatory response [81]. Structures called granulomas are 
formed around groups of Mφs infected with Mtb and are the hallmarks of 
pulmonary TB [82]. Granulomas comprise a core with Mtb-infected Mφs with a 
central necrotic area surrounded by a dense infiltrating leukocyte layer (CD4+ and 
CD8+ T cells, NK cells, B cells and neutrophils) [83-85]. Next, the entire structure is 
encapsulated by fibroblasts, which secrete an extracellular matrix shell providing an 
additional barrier separating infected cells from the lung tissue [86]. 
It is believed that containment of the Mtb infection is beneficial for the host as 
it limits the spread of the pathogens [87]. On the other hand, bacteria make use of 
granuloma as a site of multiplication and persistence [4, 84]. In addition, experiments 
on zebrafish embryos revealed that formation of granuloma at the very early stage of 
infection, before adaptive immunity develops, may contribute to spread of infection 
by massive influx of Mφs, the main target cells for Mtb [82]. Such Mtb-infected Mφs 
are able to leave primary granuloma and seed secondary infection foci [82]. Once the 
granulomas are formed the bacteria are able to persist there for years changing their 
metabolism to adapt to the hypoxic environment [81]. Maintaining a well-structured 
granuloma seems to be crucial for controlling the infection and is a result of the 
balance between host immune response and the potential of bacteria to multiply and 
disseminate [81]. 
The latent TB may last for years and never be reactivated [88]. However, 
upon immunosuppression the delicate equilibrium between immune response and 
bacteria may be disturbed and granulomas, being dynamic structures where the 
instant influx of new cells is necessary, become disrupted [87]. Such dysfunctional 
granulomas allow the bacteria to escape, spread, infect new cells and cause the 
reactivation of TB [84]. 
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1.2.2 Molecular typing of mycobacteria 
 
 
Mycobacterium tuberculosis complex (MTC) is a group of seven mycobacterial 
species causing TB, with Mtb as a major causative agent of human TB. The MTC 
consists of bacteria with identical 16S rRNA sequence and nucleotide identity higher 
than 99.9% [89]. Numerous different molecular tests were developed throughout the 
years in order to characterize strains belonging to this group. 
Spoligotyping, or spacer oligonucleotide typing, is a widely used method to 
identify members of MTC. It is based on the hybridization of the sequences 
amplified by PCR to membrane-immobilized probes, and detects the presence of 
specific DNA spacer sequences in the direct repeat region in mycobacterial genome 
[90]. As result a pattern with possible 43 dots is obtained and is used to allocate an 
isolate to the specific cluster [90]. Spoligotyping is relatively cheap, allows for 
digitalization of the data (presence or absence of the specific spacer), may be 
employed in high-throughput screenings and possesses a fair discriminatory 
capacity. Yet, this method is not able to differentiate isolates within large families, 
requires specially tailored membranes and advanced laboratory equipment and a 
potential convergent evolution leading to obtaining same patterns for different 
strains may be a problem [90]. 
Restriction fragment length polymorphism (RFLP) with the insertion 
sequence 6110 (IS6110) as a probe, is another typing method to characterize MTC. 
Genomic DNA of mycobacteria is digested by restriction enzyme PvuII [91, 92]. 
Afterwards, obtained fragments are separated by electrophoresis and transferred to 
a membrane by Southern blotting. Hybridization with IS6110 probe allows for 
visualization of the results [91, 92]. IS6110 RFLP has a very good discriminatory 
power, however such an analysis requires a large amount of mycobacterial DNA 
therefore a long culture is necessary [90]. Additionally, some Mtb strains lack IS6110 
and others have only a few copies that is too little to provide sufficient resolution 
[91]. 
Whole genome sequencing has an excellent discriminatory capacity and 
could be used as a high-resolution tool, where standard typing approaches are 
incapable of differentiating between strains. By whole genome sequencing minor 
differences between Mtb strains may be revealed, which is particularly important in 
case of organisms characterized by a general low genetic diversity such as MTC 
members [93, 94]. The correct interpretation of the sequences covering repetitive 
regions may however become a challenge [94]. Although this method still remains a 
research tool, the rapidly decreasing costs make it an interesting future genotyping 
method. 
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1.2.3 Mycobacterium tuberculosis 
 
 
1.2.3.1 Bacterium 
 
Mtb, a rod-shaped bacillus, is a major causative agent of TB. It is an obligate 
aerobe that requires oxygen to grow but has the ability to survive in hypoxic 
conditions [95]. It belongs to the genus Mycobacteria, which is divided into 
nontuberculous species and Mycobacterium tuberculosis complex (MTC) including   
M. tuberculosis, M. bovis, M. africanum, M. microtii and M. canettii, that cause disease 
in humans [96]. The Mtb genome is ~4.4 Mbp-long and was first fully sequenced in 
1998 [97]. It is GC-rich and encodes approximately 4000 genes [97]. The characteristic 
feature of the mycobacterial genome when compared with other bacteria is a high 
content of sequences coding for enzymes engaged in lipid metabolism [97]. 
Mtb bacilli are slow growing bacteria with a long doubling time, about         
24 hours, that contributes to the chronic character of disease caused by Mtb [95, 98]. 
Mtb is an intracellular bacterium, able to infect mononuclear phagocytes, namely 
Mφs and DCs [99]. Yet, it is still not clear if Mtb can actively multiply in DCs as it 
does in Mφs [99, 100]. Interestingly, Mtb DNA has been found in adipose tissue 
surrounding kidneys, stomach, lymph nodes or heart of the TB patients [101]. 
Additionally, mycobacterial DNA was detected in alveolar and interstitial Mφs as 
well as in type II pneumocytes, endothelial cells and fibroblasts of the samples from 
patients without tuberculous lung lesions [102]. 
 
 
1.2.3.2 Mycobacterial cell wall 
 
The mycobacterial cell wall contains complex waxes and glycolipids. 
Different mycobacterial species show distinct sugar substitutions in the cell wall 
glycolipids or peptidoglycolipids [96]. Such a thick and impermeable cell wall is a 
passive barrier protecting a bacterium from potentially harmful water-soluble 
substances and it is physically and functionally different from bacterial cell 
membrane [71]. Its synthesis requires a panel of specialized enzymes that are 
engaged in lipogenesis and lipolysis [97]. 
The mycobacterial cell wall is acid-fast, which means that it retains 
carbolfuchsin dye during decolorizing with acid-ethanol that allows for 
identification of mycobacteria in host tissues and visualizing them in laboratory 
specimens (Figure 2). This method was first developed in 1882 as Ziehl-Neelsen 
staining [103] and is still used in diagnosis of TB. 
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Figure 2. Acid fast staining of Mφs infected with Mtb. Mycobacteria are visualized as red rods that 
retained carbolfuchsin dye during destaining with ethanol-acid. Next, cells were counterstained with 
methylene blue. 
 
A distinctive feature of the mycobacterial cell wall is a presence of highly 
structured macromolecules, peptidoglycan-arabinogalactan-mycolic acids and also 
different glycolipids, including phosphatidylinositol mannosides (PIMs), 
lipomannan (LM) and lipoarabinomannan (LAM) [104] (Figure 3). A rigid scaffold is 
made of peptidoglycan linked to arabinogalactan, which is esterified at its distal, 
non-reducing end by the mycolic acids [105]. Glycolipids and proteins are localized 
between peptidoglycan and mycolic acid layers [105]. Phosphatidyloinositol (PI) 
anchors form foundations for mycobacterial glycolipids [105]. PIMs are PIs with 
several mannoses attached, and di- (PIM2) and hexa-mannosylated (PIM6) forms are 
the most abundant in the mycobacterial cell wall [106, 107]. LM is a PI with longer 
and branched mannose chain, while LAM possesses an arabinnan part [105, 108]. 
The cell wall of slow growing mycobacteria, e.g. M. tuberculosis and M. bovis, 
contains LAMs with mannose caps at the end of arabinnan branches – mannose-
capped LAMs (ManLAMs) [109]. It has been observed that ManLAM from a single 
source is heterogeneous with regard to size, branching and acylation [104]. 
Structurally LAMs can be divided into ManLAM, PILAM and AraLAM. 
PILAM is LAM capped with phosphoinositides and is a part of the cell wall of fast 
growing mycobacteria (M. smegmatis, M. fortuitum), whereas AraLAM, specific for 
M. chelonae, is LAM lacking any capping motifs [110, 111]. PILAM binds to CD14 and 
TLR2 and induces production of chemokines and pro-inflammatory cytokines [110, 
112-114]. It is also known to be cytotoxic, by inhibiting protein kinase C and 
impairing several intracellular pathways [115]. AraLAM is not as immuno-
stimulatory and cytotoxic as PILAM, and the lack of the capping motifs has been 
associated with its lesser activity [116, 117]. Interestingly, both PILAM and AraLAM 
weakly interact with DC-SIGN, which confirms an affinity of this C-type lectin for 
highly mannosylated structures [118]. 
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Figure 3. Schematic representation of mycobacterial cell wall structure. Adapted with changes from 
[104]. 
 
 
Many cell wall compounds were found to play a role in regulating the 
immune response to Mtb infection or to be engaged in modulating host cell 
mechanisms to facilitate bacterial growth and persistence [119-123]. The 
mycobacterial cell wall is also a challenge for development of new drugs as they 
have to penetrate through this thick, non-permeable, hydrophobic barrier [124]. 
Receptors on the host cell surface specifically interact with distinct 
mycobacterial cell wall components. MR, for instance, associates favorably with 
higher-order PIMs and this interaction is dependent on PIM acylation degree [125]. 
On the contrary, DC-SIGN equally well recognizes LM, ManLAM and PIMs of all 
mannosylation and acylation degrees [125]. Thus, structural differences between 
mycobacterial cell wall compounds influence the interaction of bacterium with host 
cell. 
 
 
 
1.2.4 Immune system and mycobacteria 
 
 
1.2.4.1 Activation and modulation of immunity in Mtb infection 
 
The host defense against Mtb requires both a vigorous innate and cellular 
immune responses. Both Mφs and DCs are target cells for Mtb [71, 81, 126-128], and 
mycobacteria interact with receptors on the surface of these cells, which leads to 
internalization and infection. The main receptors engaged in such interactions on 
Mφs are MR and complement receptor-3 (CR-3), whereas DC-SIGN, which is 
expressed by freshly isolated lung DCs, plays a major role in infection of DCs [129]. 
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It has been shown in the mouse model that DCs undergo functional activation 
following infection with bacillus Calmette–Guérin (BCG) in vivo and that they are 
able to initiate immune response to mycobacteria during early phase of infection 
[126]. At this phase Mtb are transported from the lungs to the draining lymph nodes 
by infected lung myeloid DCs [77]. However, such DCs are not fully efficient in 
initiating Mtb-specific CD4+ T cell responses, as presentation of mycobacterial Ags 
by MHC class II is limited without affecting expression level of MHC class II [77]. 
Moreover, Mtb has been demonstrated to interact with TLRs, namely, TLR2, TLR4 
and TLR1/6 and thus to trigger a cascade of intracellular signaling leading to 
production of pro-inflammatory cytokines [130-132]. 
Importantly, the effect of mycobacterial infection is not limited merely to 
infected cells but may also in a bystander manner extend to remotely localized cells. 
For example, mycobacterial lipids were found in extracellular vesicles released by 
infected Mφs and also in uninfected bystander cells [133]. Mycobacterial Ags were 
found to be cross-presented to T cells by uninfected DCs [134]. Furthermore, it has 
been demonstrated in vitro that uninfected bystander DCs were preferentially 
matured during Mtb infection, whereas Mtb-infected DCs from the same culture 
displayed only minimal phenotypic maturation [135]. 
Another important feature of mycobacteria is their ability to manipulate the 
processes leading to the infected cell death [136]. The virulent strains predominantly 
cause necrosis rather than apoptosis [137, 138]. This is beneficial for mycobacteria 
because death by apoptosis maintains continuity of cell membrane and therefore 
restricts bacterial spread, while necrosis is associated with cell disruption and release 
of bacteria to the extracellular compartments [136, 139]. It is widely accepted that 
preventing apoptosis is related to prolonged bacterial survival in infected cells [140] 
possibly due to delayed activation of T cells [141-143]. Induction of apoptosis in 
infected cells is more pronounced for non-virulent mycobacteria, e.g. M. bovis BCG, 
M. smegmatis or the attenuated M. tuberculosis H37Ra strain [137, 140, 144, 145]. 
Interestingly, the avirulent Mtb strain H37Ra is able to induce apoptosis in bystander 
Mφs, however such a reaction is dependent on the direct contact of bystander Mφs 
with infected cell [146]. The apoptosis triggered by mycobacteria is controlled by 
miRs, such as let-7e or miR-155 [147, 148]. For example, induction of miR-155 in 
response to M. bovis BCG activates caspase 3 and triggers apoptosis in Mφs [147]. 
Mycobacteria are able to prevent acidification of phagosomes and fusion of 
phagosome with lysosomes [149]. Therefore mycobacteria residing in such 
phagosomes are protected from harsh conditions of the lysosome and able to avoid 
degradation, subsequent processing and presentation of mycobacterial Ags [150]. 
Mycobacterial glycolipid, ManLAM, is responsible for phagosomal maturation block 
[119, 120]. Such phagosomal maturation arrest creates a niche for mycobacteria to 
live in and multiply inside the phagocyte [150]. Interestingly, it is not quite clear 
whether mycobacteria multiply inside the phagosome. Some groups reported that 
mycobacteria are strictly confined to the phagosomal compartment, while others 
observed their translocation to the cytosol [128, 151-155]. These two scenarios are not 
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mutually exclusive and it is possible that both co-exist widening a niche in which 
Mtb may reside inside target cells. 
In most cases a sufficient immune response develops to control the infection 
and to prevent from development of active TB disease. Dominant response of Th1-
type seems to be critical and it is associated with activation of specific cells and 
production of cytokines that act as both effectors and regulators of immunity to 
mycobacterial infection [156]. Hence, an impaired immune system may allow for 
reactivation of latent infection or result in rapid progression of primary Mtb 
infection to disease [157]. This is often observed in latently infected patients 
undergoing cancer chemotherapy, HIV-positive individuals and those with 
compromised immune systems due to other pathological conditions or malnutrition. 
Conversely, an excessive and unbalanced immune response is also detrimental. It 
causes immunopathology with extensive necrosis in granulomas resulting in failure 
to contain and control Mtb infection and exacerbation of the disease [158-161]. 
Thus, the controlled inflammatory reaction to the mycobacterial infection is 
crucial for the formation and maintenance of granulomas, typical TB-related 
structures [162]. Well-sealed non-progressive granulomas ensure Mtb isolation and 
prevent from its spread but also provide a relatively favorable environment in which 
bacilli can survive for years [87]. 
 
 
1.2.4.1.1 Role of the cytokines 
 
Mtb infection triggers the production of a large number of soluble mediators 
of inflammation. Many cytokines released in response to Mtb infection are essential 
for controlling the infection, but their over-expression may also lead to 
immunopathology [157]. Cytokine patterns expressed by distinct cell types differ 
and play complementary roles often balancing each other functions. Mφs, for 
instance, release mainly TNF, IL-1, IL-6 and IL-18, whereas DCs produce large 
amounts of TNF and IL-12 [127]. Both DCs and Mφs secrete IL-10, a potent inhibitor 
of IL-12 production [127, 163]. 
TNF is critical for controlling Mtb infection and its role is non-redundant. 
However, excessive production of TNF is detrimental and causes immunopathology 
[164], while its insufficient levels may lead to reactivation of latent Mtb infection 
[165]. The latter phenomenon is observed in rheumatoid arthritis patients 
undergoing TNF-neutralizing therapy [166]. Deficiency in production of TNF leads 
to inadequate activation of phagocytes and lack of proper production of chemokines 
which in turns impairs migration of cells to the site of infection, malformation of 
granulomas and spread of bacteria [156, 167]. 
Mtb induces IL-12 but its expression in the infected lung is not high. Still, 
local production of IL-12 within the draining lymph nodes seems to be crucial for 
initiation of optimal IFN-γ production that is critical for the control of the Mtb 
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infection [156]. Interestingly, people with congenital deficiencies in the IL-12/23-
IFN-γ circuit displayed increased susceptibility to infections caused even by less 
virulent mycobacteria [168]. 
The role of IFN-γ in Mtb infection is widely acknowledged, as its protective 
effects have been observed both in vitro [169] and in vivo [170, 171]. This cytokine is 
produced mainly by CD4+ and CD8+ T cells but also by cells of innate immunity, 
including γδT cells, NKT cells, and NK cells. IFN-γ produced by innate cells may be 
especially important in Mtb-HIV co-infected individuals with a severe depletion in T 
cell compartments [156]. 
Another cytokine playing a major role in Mtb infection is IL-1. Experiments 
with knock-out mice lacking either IL-1 receptors or IL-1β itself revealed a high 
susceptibility of such animals to Mtb infection resulting in increased pulmonary 
bacterial loads and decreased survival [172-174]. In humans, the role of IL-1 
signaling in host resistance to Mtb has also been appreciated. Studies investigating 
polymorphisms in IL-1 and its receptor genes revealed their correlation with TB 
progression and course of the disease [175, 176]. Blocking of IL-1 receptor is a part of 
rheumatoid arthritis therapy and, similarly to anti-TNF treatment, leads to increased 
risk of reactivation of TB [177, 178]. 
Mtb infection also induces abundant amount of IL-6. Its role has been 
associated with initiation of the appropriate T cell activation and production of   
IFN-γ [156]. Surprisingly, while Mtb infection of IL-6 knock-out mice first led to 
increase in bacterial burden, these mice were still able to control infection and 
develop protective immunity to secondary Mtb infection [179]. Also rheumatoid 
arthritis therapy with antibodies against IL-6R was not associated with an increased 
risk for TB incidence among treated patients [180]. 
IL-10 is an immuno-regulatory cytokine produced by many T cell subsets, B 
cells, neutrophils, Mφs, and some DC subsets and it plays a not yet fully defined role 
during Mtb infection [163]. Elevated IL-10 levels may lead to decreased production 
of TNF and IL-12p40, which in turn results in failure to control Mtb infection [156, 
163, 181, 182]. Studies in IL-10-deficient mice generated contradictory results where 
either TB progression [183] or reduction [184] in bacterial load in both the lungs and 
spleens were observed. 
 
 
1.2.4.1.2 Immunomodulatory roles of mycobacterial cell wall components 
 
Surface-exposed mycobacterial glycolipids and glycopeptidolipids are 
known to interact with receptors on Mφs and DCs and facilitate phagocytosis and 
subsequent infection of such cells [107, 185]. 
ManLAM interacts with C-type lectins, such as mannose receptor (MR) and 
DC-SIGN [125]. The high content of ManLAM in the Mtb cell wall and its systemic 
presence during TB suggest that it may exert important immuno-modulatory 
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functions [186, 187]. Indeed, ManLAM stimulates phagocytosis by interacting with 
MR on Mφs and thus mediates binding and entry of Mtb to the host cell [188-190]. 
Another important feature of ManLAM is its ability to interfere with phagosome-
lysosome fusion that in turn allows bacteria to survive inside phagocytes [119, 191]. 
ManLAM derived from the cell wall of virulent Mtb promotes NO production by 
activated Mφs [192]. Furthermore, such ManLAM specifically stimulated production 
of IL-1β and TNF by monocytic cells (THP-1) [193], it was able to trigger TNF release 
from human blood monocytes and murine Mφs as well as TNF and IL-1β expression 
in mice in vivo [122, 194, 195]. The ability of ManLAM to regulate IL-12 release from 
DCs is controversial. Some authors found this glycolipid to be unable to trigger      
IL-12, or even to inhibit IL-12 production induced by distinct signals [196, 197]. 
Other groups, including ours, found that ManLAM is actually a potent inducer of  
IL-12 from DCs and enhances effects of additional pro-inflammatory stimulus, i.e. 
LPS [198] (see also the Results and Discussion Section and Paper I). Of note, 
experiments with M. bovis BCG mutants lacking ManLAM capping motifs revealed 
that both mutated and wild type strains induce comparable levels of IL-12p40 and 
IL-10 from stimulated DCs [199]. 
The role of ManLAM has also been investigated in the context of apoptosis 
modulation. ManLAM was found to inhibit apoptosis caused by Mtb infection 
without interfering with NO and TNF production [123]. Moreover, ManLAM affects 
levels of calcium ions in Mφs in CD14- and MR-dependent manner [200], modulates 
DC function [198] and acts as chemoattractant to T cells, monocytes and Mφs [121, 
201]. 
LMs derived from distinct mycobacterial species are able to induce apoptosis 
and production of TNF, IL-12 and IL-8 [116, 202]. Such a strong pro-inflammatory 
response triggered by LM results from its interaction and signaling through TLR2 
[110, 203]. Interestingly, a recent finding identified Mtb LM as an inhibitor of TNF 
release rather than its inducer [204]. 
PIM-induced production of immuno-regulatory cytokine, IL-10, has been 
linked to suppression of the inflammatory response during allergic airway disease 
[205]. Additionally, PIM2 is a chemoattractant for NKT cells [206]. Of note, PIMs, 
similarly to PILAM or LM, signal through TLR2 [207]. Furthermore, PIM6, but not 
PIMs of lower mannosylation degree, interact with MR while PIMs of all orders 
could bind to DC-SIGN [125, 199]. Mycobacterial PIMs, independent of TLR2, are 
able to inhibit signaling from TLR4 leading to the production of NO, chemokines 
and pro-inflammatory cytokines [7, 208]. 
Finally, it has been postulated that a ratio between different glycolipids in the 
mycobacterial cell wall may be responsible for the virulence of specific bacterial 
species or strains [110]. Moreover, alterations in the cell wall composition related to 
the latent state of bacteria were observed [209]. Thus, it suggests that the 
mycobacterial cell wall is a dynamic structure and its composition may impact the 
immunogenicity and immunomodulatory properties of mycobacteria. 
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1.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
 
 
 
1.3.1 HIV and AIDS – epidemiology 
 
 
According to WHO, it was estimated that worldwide a total of 34 million 
people were living with HIV in 2010, and that yearly 2.7 million individuals were 
newly infected [210]. Globally there is a declining trend in the HIV incidence; 
however, there are clear differences between geographical regions. The incidence of 
HIV in highly affected Sub-Saharan regions of Africa noted a decreasing trend 
during the past years, whereas in other locations the incidence of HIV infection is 
still on the rise [210]. Annually, about 1.8 million people die from acquired 
immunodeficiency syndrome (AIDS)-related diseases, even though introduction of 
anti-retroviral therapy (ART) has been estimated to avert about 2.5 million deaths in 
low- and middle-income countries [210]. Thus, HIV is still a leading infectious cause 
of death worldwide [68]. There are two related types of HIV (HIV-1 and HIV-2) and 
both cause AIDS. HIV-1 is more pathogenic and infection caused by HIV-1 has 
resulted in the pandemic spread of HIV, while HIV-2, mainly endemic in West 
Africa, is the cause of AIDS in a reduced number of individuals with a slower 
disease progression rate [211-213]. 
 
 
 
1.3.2 HIV-1 
 
 
1.3.2.1 Genome and structure 
 
The HIV-1 is a member of the Lentivirus genus and the Retroviridae family, 
and is globally the major causative agent of AIDS [214]. The genome of HIV-1 
consists of ~10 kb single-stranded RNA with nine open reading frames [215]. The 
HIV-1 genome codes for structural proteins (encoded by the gag gene), envelope 
proteins (encoded by the env gene), three enzymes (encoded by the pol gene) and six 
regulatory and accessory proteins (Tat, Rev, Nef, Vif, Vpr and Vpu) [216, 217] 
(Figure 4A). 
The HIV-1 virion is enveloped by a lipid bilayer that is derived from the 
membrane of the infected host cell and is acquired by the virus during a budding 
process [218] (Figure 4B). Among proteins found in the viral particles are host-
derived proteins, e.g. actin, ubiquitin, MHC molecules, and the viral envelope 
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glycoprotein complex, consisting of surface gp120 and trans-membrane gp41 
proteins in trimeric form [217, 219]. Under the envelope there is a matrix layer made 
up by the matrix protein p17 that in turn surrounds a conical capsid built up by the 
capsid protein p24 [217]. The capsid contains two copies of viral genomic RNA [216]. 
HIV-1 RNAs are stabilized by nucleocapsid proteins p7 [217]. The capsid also 
contains three viral enzymes: protease, reverse transcriptase and integrase. During 
the life cycle HIV-1 produces also accessory and regulatory proteins engaged in 
regulation of virus replication and in host immune response evasion [214, 220]. 
 
Figure 4. Schematic representations of HIV genome arrangement (A) and virion structure (B). Adapted 
with changes from [212, 216]. 
 
 
1.3.2.2 Life cycle 
 
The very first stage of the HIV-1 infection involves virus interaction with a 
potential target cell. The primary receptor for HIV is CD4, but host cell entry also 
requires virus interaction with a co-receptor, usually CCR5 or CXCR4 [221]. The 
involvement of other receptors, such as C-type lectins, syndecans or galactosyl 
ceramide, has also been demonstrated to play role in virus attachment to the target 
cell that in turn may lead to enhancement of viral entry and infection [16, 214, 222-
224]. 
Upon entering the host cell viral RNA is retro-transcribed into double-
stranded DNA (dsDNA) by the viral reverse transcriptase enzyme. Then the dsDNA 
is translocated to the nucleus and subsequently inserted by the viral integrase into 
the host genome, where it can remain latent, as a provirus, as long as the cell is alive 
[216, 218]. With the help of the host cell transcription machinery the viral replication 
starts at the viral promoter region, long-terminal repeats (LTRs) (Figure 4A) [218]. 
The rate of the replication depends greatly on the activation state of infected cell, and 
therefore HIV-1 in proviral form may persist for years in resting cells and be 
activated upon their stimulation [225, 226]. From HIV-1 mRNAs new copies of viral 
genomic RNA and viral proteins are generated in a highly regulated manner in 
order to produce new viral particles [218]. Viral envelope proteins are processed by 
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the cellular machinery: endoplasmic reticulum and Golgi apparatus, and are 
eventually targeted to the cell membrane [218]. Two copies of genomic RNA are 
associated with nucleocapsid proteins and precursor Gag and Pol proteins, and then 
transported to the cell surface [215, 216]. There, the viral particle acquires its 
envelope consisting of cellular lipid bilayer and proteins which are anchored in it, 
including the viral envelope glycoproteins [215]. Lastly the viral protease enzyme 
cleaves the Gag and Pol precursor proteins allowing for the capsid formation and 
maturation of the budding virus and its release into the extracellular compartment 
[216]. 
HIV regulatory proteins play a major role in the HIV replication process. Tat 
is a powerful transactivator of the viral gene expression and Rev participates in 
stabilization and transport of singly- or unspliced viral transcripts from the nucleus 
to the cytoplasm allowing for the full synthesis of the virus [215, 216, 227]. In 
addition, Tat is secreted from infected cells and influences the neighboring cells in a 
bystander manner in order to modulate their functions, e.g. by their activation and 
increasing the expression of HIV co-receptors [228]. The accessory proteins, Nef, 
Vpu, Vif and Vpr, also participate in regulation of the virus replication but also 
counteract immune response mechanisms. Nef has been implicated in CD4 and 
MHC class I down-regulation on the infected cells affecting their function [215, 229]. 
Vpu participates in the release of newly produced viral particles from the cell 
surface, but also promotes CD4 degradation and interferes with CD1d expression 
and antigen presentation [216, 220, 230]. Vif neutralizes anti-viral cellular 
mechanisms, including APOBEC3 [220], while Vpr plays a role in nuclear 
translocation of the provirus, modulates the cell cycle and causes the cell division 
arrest or cell death [220]. 
 
 
1.3.2.3 Course of the HIV-1 infection 
 
HIV-1 is most often transmitted upon sexual exposure, but the transmission 
may also occur upon contact with blood of infected persons e.g. during blood 
transfusion or by needle sharing between intravenous drug users [210]. Generally, 
virus particles and HIV-1-infected cells in blood and genital secretions are the main 
source of virus transmission [214]. Other body fluids, such as saliva, tears, urine and 
sweat may contain virus particles but due to antiviral immune components these 
viruses appear to be non-infectious, or markedly less infectious [214]. HIV-1 may 
also be transmitted from infected mothers to their children, either before birth in the 
uterus, during delivery or through breast milk at nursing of the newborn. 
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In principle, the course of the HIV infection can be divided into three stages:  
 
1) The primary, or acute, infection phase with high levels of circulating virus in 
the peripheral blood before fully developed immunity; 
2) The chronic infection phase, when the virus level is maintained at a stable 
level partially controlled by the immune system; 
3) The AIDS phase, defined as immunodeficiency following CD4+ T cell 
number reduction below 200 cells/mm3 and the onset of opportunistic 
infections and malignancies [214].  
 
 
Primary HIV infection may be asymptomatic or manifested by a panel of flu-
like symptoms, including fever, rash, muscle ache, and nausea [231]. Viral RNA can 
be found in the blood as early as two days after infection, and peak viremia appears 
about two to three weeks later [214]. Primary infection lasts for 4-6 months and is 
characterized by high HIV levels in the blood accompanied by immune system 
activation. During this time the number of CD4+ T cells in peripheral blood is 
transiently decreased while amount of CD8+ T cells is elevated [214, 232]. Next, 
CD4+ T cell level in the blood may return to almost normal value and then again 
steadily decrease over the course of HIV infection and progression to AIDS [214]. 
The fraction of infected, circulating CD4+ T cells rarely reaches 1% [233]. However, it 
has been demonstrated that CD4+ T cells in gut-associated lymphoid tissue (GALT) 
are not fully recovered in patients successfully treated with ART [234]. Furthermore, 
the same study revealed that the proportion of CD4+ T cells infected with HIV-1 was 
higher in GALT than among PBMCs and that a cross-infection between GALT and 
blood compartment was noted [234]. Yet, an overall CD4+ T depletion is not solely 
related to direct HIV infection of these cells. In addition, hyperactivation of the 
immune system caused by chronic HIV-1 Ag exposure and persistent inflammation, 
together with impaired mechanisms responsible for virus eradication, lead to 
increased CD4+ cell turnover and CD4+ cell depletion [235-237]. Abs against HIV 
proteins usually appear 1-2 weeks post-infection [214]. Among Abs produced as a 
result of HIV infection are neutralizing Abs, however, virus escape mutants 
constantly emerge making these Abs less effective [238]. Also non-neutralizing and 
even enhancing Abs, that may opsonize the virus and facilitate its entry to the 
phagocytic cells, develop [239, 240]. 
The chronic stage of the infection, with clinical latency, defined as an 
asymptomatic phase with no AIDS symptoms usually lasts around ten years in 
untreated individuals, but upon initiation of antiretroviral therapy (ART) the 
asymptomatic phase may be significantly prolonged [241, 242]. According to WHO 
guidelines, AIDS is diagnosed when blood CD4+ T cell count is less than 200/mm3 
and opportunistic infections or malignancies develop, including pulmonary 
tuberculosis, recurrent pneumonia, invasive cervical cancer and several other clinical 
conditions [243]. 
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The virus phenotype may influence the course of HIV-1 infection (reviewed 
in [244]). The switch in HIV-1 co-receptor use, from CCR5 to CXCR4, as observed in 
30-80% of AIDS patients depending on the HIV-1 subtype, has been associated with 
accelerated disease progression [245]. However, the remaining proportion of 
infected individuals may eventually also progress to AIDS despite harboring virus 
only restricted to CCR5 [244]. 
Nowadays, upon implementation of ART the progress to AIDS is slowed 
down. Such a therapy includes several anti-retroviral drugs targeting distinct stages 
of the HIV-1 replication cycle. Recommended drug combination should include at 
least three drugs targeting more than one step of the HIV-1 replication cycle [246]. 
Commonly used drugs belong to reverse transcriptase inhibitors, integrase 
inhibitors, protease inhibitors and HIV-1 co-receptor inhibitors [246, 247]. Drug 
resistance, either primary, when an individual is infected with resistant HIV, or 
acquired during ART, is an emerging problem [247, 248]. In addition, possible side 
effects, drug-related toxicity and development of malignancies must be taken into 
consideration when choosing the therapy [242]. Successful ART results in reduction 
of viral load to residual low levels, but at present there is no therapy available that 
leads to complete elimination of the virus [249, 250]. 
 
 
1.3.2.4 Cells of innate immunity and their interactions with the virus 
 
The main target cells for HIV-1 are the CD4+ T cells which efficiently support 
viral replication and virus spread to the new cells. Still, the spectrum of cells infected 
by HIV-1 is broad, including Mφs and DCs. Even though the route of HIV-1 
transmission may vary, APCs can often be the first cells to encounter the virus. These 
cells may either be infected or the virus can also bind to them for transfer from the 
periphery to lymph nodes and subsequent transmission to CD4+ T cells, in a process 
called trans-infection. Other innate immune cells, including NK, NKT and γδT cells 
may also play important roles as HIV targets, HIV reservoirs and by modulating 
immune response to the viral infection. 
 
 
1.3.2.4.1 Dendritic cells and HIV-1 
 
Langerhans cells and other DCs present in the skin, in the mucosa and in the 
blood express CD4, CCR5 and CXCR4 and therefore they often become infected with 
HIV-1. These cells may then spread the virus to other cell types. Studies on simian 
immunodeficiency virus (SIV) infection in Rhesus macaques revealed that mucosa-
associated DCs bound or were infected by the virus and subsequently could transmit 
the virus to CD4+ T cells [251, 252]. Additionally, vaginal and ectocervical DCs, but 
not Mφs or lymphocytes from the same localization, have been shown to be the first 
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cells infected with HIV-1, whereas four days later viral replication was mostly 
associated with lymphocytes [253]. It has also been reported that both types of DC 
subsets, mDCs and pDCs, are susceptible to infection with CCR5- and CXCR4-
restricted viruses in vitro [254]. The replication in DCs appears, however, to be much 
less productive than in the CD4+ T cells and number of infected DCs in vivo is much 
smaller as compared with HIV-infected CD4+ T cells [255, 256]. The lower virus 
production of DC has been ascribed to relatively low levels of HIV-1 receptors on the 
DC surface, fast degradation of internalized virions and existence of intrinsic HIV-
limiting cellular factors, e.g. APOBEC3G [16, 257-259] and SAMHD1 [260, 261]. 
Interestingly, DCs can efficiently mediate HIV-1 infection of T cells. This 
mechanism, known as DC-mediated trans-infection or trans-enhancement, is a multi-
stage process. DCs may transmit HIV-1 to target cells without being infected, which 
is possible when virus is taken up by DCs, while not degraded, and later released. It 
has been suggested that C-type lectins, including DC-SIGN and MR, play role in the 
DC-mediated HIV trans-infection [259, 262]. Transmission of the virus usually occurs 
when DCs get into close contact with CD4+ T cells during formation of the 
immunological synapse, in this case known as the virological synapse. As reported, 
productive HIV infection of DCs is required for long-term virus transmission, while 
shortly after virus exposure DCs mediate trans-infection to T cells without being 
infected [258, 263, 264].  
DCs are also known as virus reservoirs. This is particularly well established 
for follicular DCs, which reside in the lymph nodes and may capture virus without 
getting productively infected with HIV-1. In spite of that, they may play a major role 
in HIV-1 pathogenesis because of their exceptionally high pathogen harboring 
capacity [265]. Soon after infection large quantities of virions can be trapped on the 
surface of follicular DCs and retained there, while maintaining their high infectivity 
even in the presence of neutralizing Abs [266]. Furthermore, location of follicular 
DCs in the lymph nodes in proximity to a pool of CD4+ T cells that are particularly 
susceptible to HIV infection helps to spread the virus over long periods of time [16]. 
Such an accumulation of the virus occurs rapidly, before the symptoms related to 
infection are recognized and treatment is implemented [267]. 
Notably, DC function is modulated by HIV-1 contributing to HIV-associated 
immune system dysregulation. DCs isolated from HIV-positive individuals display 
down-regulated levels of CD80 and CD86 co-stimulatory molecules which results in 
impaired efficiency in stimulation of T cells [16]. In addition, HIV-1 accessory 
proteins are engaged in HIV immune system evasion and DC-mediated spread of 
the virus, e.g. Tat induces release of chemoattractants facilitating interaction of T 
cells with HIV-1-infected DCs and Nef is able to down-modulate Ag presenting 
molecules on the DC surface [16].  
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1.3.2.4.2 Macrophages and HIV-1 
 
Upon sexual contact Mφs residing in the subepithelial mucosa can also be 
infected by HIV-1 [268]. Level of virus replication in Mφs is rather low owing to 
intracellular limiting mechanisms. Despite this, it is thought that Mφs may constitute 
an important virus reservoir. Although it is a resting memory CD4+ T cell 
population that is a main HIV reservoir, also Mφs are considered to harbor 
infectious viral particles for a long time [249]. Studies have suggested that even 
during successful ART HIV-1 may remain hidden in Mφs [269]. HIV-infected Mφs 
can survive in the body for several weeks and even after prolonged periods of time 
efficiently transmit the virus to the CD4+ T cells [270, 271]. Chronically infected Mφs 
are able to start producing new viral particles upon stimulation with pro-
inflammatory cytokines, namely TNF, IL-6, IL-1β or IL-18 [272-274]. 
Interestingly, a model where Mφs could be differently activated during 
progression of HIV infection has been proposed. According to this concept first stage 
of infection is accompanied by the presence of classically activated Mφs with rapid 
formation of viral reservoirs [275]. Subsequently, alternatively activated Mφs appear 
followed by augmented production of IL-10 resulting in deactivation stage of Mφs as 
seen at the late stages of AIDS [275]. 
The ability of primary Mφs to support HIV replication in vitro is variable and 
donor-dependent [276]. Studies on HIV isolates derived from the patients in whom 
there was no co-receptor switch and the virus remained strictly CCR5-tropic have 
shown that viruses isolated at the later stage were more prone to active replication in 
Mφs than viruses appearing early on [277]. 
It has been observed that infection with HIV-1 results in manipulation of the 
functions of Mφs to facilitate viral spread and hampers Mφ antimicrobial 
mechanisms [276]. For instance, Nef protein induces release of MIP-1α and MIP-1β, 
which trigger recruitment of T cell to the site of infection and enable spread of the 
infection [278]. Interestingly, HIV-1 has been suggested to make use of cellular 
autophagosomal machinery in Mφs to process Gag protein while blocking later 
stages of autophagy in order to protect viral Ags from presentation in MHC class II 
context [279]. Moreover, the ability of Mφs to phagocytose opsonized pathogens has 
been shown to be impaired during HIV infection [280]. 
 
 
 
1.3.3 Pathogenesis of HIV-1 infection 
 
 
HIV-1 infection eventually leads to CD4+ T cell depletion, which may be 
explained by dysregulation of the immune system that results in malfunctions of the 
tight control of the activation and survival of cells, followed by chronic immune 
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activation and exhaustion. In addition HIV-1 infection has been linked to 
suppression of hematopoiesis, changes in phenotypes of circulating lymphocytes 
and B cell abnormalities such as polyclonal activation or lack of Ab response to new 
antigens [214]. Cells of innate immunity are also severely affected, as observed by 
reduced phagocytosis, decreased Ag presentation capacity and modified cytokine 
and chemokine profiles [281]. 
General dysregulation of the immune system leads not only to impaired 
response to the pathogens, but also affects the normal function of many organs, 
including heart, kidneys, lungs and joints [214]. In addition, HIV-1 infection has been 
associated with several malignancies caused either by loss of anti-cancer immunity 
or by increased proliferation of cancerous cells triggered by the pro-inflammatory 
conditions [282, 283]. Kaposi’s sarcoma is a very common malignancy seen during 
HIV infection and is associated with human herpesvirus 8 [284]. Other dysplasia 
often found in HIV patients is human papilloma virus-associated cervical cancer and 
Epstein-Barr virus-associated lymphoma that both are AIDS-defining conditions 
[243]. 
Another common complication related to the HIV-1 infection is an injury of 
the nervous system. Neurological dysfunctions might derive from a direct viral 
infection, toxicity of viral proteins, emergence of immunosuppression-related 
opportunistic infections, HIV-associated cancers, side effects of ART, but most often 
they display multiple etiologies [285]. 
Overall the time from the infection to the development of AIDS may vary 
and depends on many factors, including genetic host factors, viral factors, other co-
infecting pathogens, e.g. Mtb, affecting the immune system of the HIV-infected 
individual, and also so-called life-style factors such as alcohol abuse, smoking and 
drug use [214]. 
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1.4 CO-INFECTIONS WITH MTB AND HIV-1 
 
 
 
1.4.1 Epidemiology and clinical considerations 
 
 
According to WHO in 2010 there was 0.35 million deaths from TB associated 
with HIV infection and 13% of TB cases occurred among HIV-infected people. The 
likelihood of developing active TB among HIV-positive individuals is 21-34 times 
greater than among those that are not HIV-infected [286]. In other words, the risk of 
developing active TB in immunocompetent adults is estimated to be 5-10% during 
lifetime, while in HIV-infected people it is increased to 5-15% annually [287]. 
Generally, HIV infection is the strongest risk factor for developing TB [288]. Also the 
likelihood of re-infection with Mtb is augmented in HIV-positive individuals due to 
an impaired ability to mount long-lasting protective immunity [289]. 
The diagnosis of TB is challenging in the HIV co-infection setting. The 
sensitivity of conventional tests diagnosing Mtb infection is decreased and 
additionally the clinical presentation of TB might be atypical [290]. Implementation 
of ART has resulted in a rise of CD4+ T cell count and partial immune system 
restoration, that in turn has significantly decreased TB incidence [288]. ART also 
correlates with drop in number of extrapulmonary TB cases [291]. Nonetheless, the 
overall TB incidence rate for HIV-positive individuals undergoing successful ART 
still remains at least two-fold higher than for those without HIV [288]. 
Paradoxically, introduction of ART for some co-infected patients may result 
in clinical deteriorations. Immune reconstitution inflammatory syndrome (IRIS) 
appears when ART-related recovery of the immune system leads to excessive 
inflammatory responses against pathogens and/or tumors [288]. It is manifested by 
high fever, respiratory and renal failures, lymphadenopathies, and generally 
worsening of the infection symptoms [288, 292]. TB-associated IRIS either accelerates 
inflammatory reaction to ongoing active TB or activates latent, so far undiagnosed 
Mtb infection [293]. The incidence of TB-associated IRIS reaches 40% depending on 
many associated conditions, and appears usually within first 4-8 weeks after ART 
initiation [294-296]. In addition to common manifestations of IRIS, a TB-associated 
one is related to augmentation of pulmonary infiltrates and expansion of lung 
lesions [297, 298]. 
The general dysregulation of the immune system during Mtb-HIV-1 co-
infection leads to rapid progression of both diseases. Disrupted homeostasis between 
pro- and anti-inflammatory cytokines, manipulation of apoptosis processes and 
impaired effector functions of immune cells account for detrimental pathogen 
synergy in people concurrently infected with HIV-1 and Mtb [299]. 
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1.4.2 Mechanisms of Mtb-HIV-1 synergy 
 
 
1.4.2.1 Impact of HIV-1 on TB progression 
 
HIV infection has a great impact on general immune system homeostasis that 
leads to immunosuppression and failure in controlling Mtb infection. This includes 
altering of the cytokine and chemokine production and Ag presentation, apoptosis 
dysregulation, disruption of granuloma structures and control of dormant Mtb 
infection [300]. 
The risk of developing active TB in HIV-1-positive patients is higher than in 
HIV-uninfected individuals and is inversely correlated with CD4+ T cell count [301, 
302]. In addition, not only the number, but also functionality of CD4 T cells in 
bronchoalveolar lavage (BAL) of co-infected patients is impaired, i.e. their ability to 
release cytokines upon mycobacteria-specific stimulation [303]. 
Production of cytokines in response to Mtb infection is highly modulated by 
HIV-1. It has been demonstrated that TNF production by Mtb-infected alveolar Mφs 
isolated from HIV-1-positive patients was reduced as compared with cells from HIV-
negative individuals [304]. Impaired TNF production was also noted in situ in lung 
granulomas of Mtb-HIV-1 co-infected individuals and this was accompanied by the 
presence of abnormally formed granulomas [305]. This effect was assigned to HIV 
protein Nef that dampens the Mtb-triggered production of TNF in Mφs [306]. Also 
IFN-γ production is defective in HIV-positive persons, which may explain the 
decreased sensitivity of TB diagnostic tests based on Mtb-specific IFN-γ release [307, 
308]. IL-10 is known to be released as the result of high levels of IL-6 and TNF, and 
in this way inhibit excessive inflammatory response in a negative feedback manner 
[309]. Interestingly, the IL-10 level in BAL fluid from HIV-positive individuals is 
elevated when compared with HIV-negative BAL, which suggests that Th1-
dependent control of Mtb infection is down-regulated [310]. IL-10 prevents 
phagosome maturation during Mtb infection [311], suggesting that HIV-triggered 
conditions may help Mtb to survive and multiply in the lungs. 
Strikingly, Mtb-specific CD4+ T cells are highly susceptible to infection with 
HIV and are preferentially depleted during course of the co-infection [312, 313]. Also 
HIV-infected Mφs facilitate intracellular growth of mycobacteria [314, 315]. In case of 
alveolar Mφs it could be the result of Mtb-induced apoptosis observed in cells 
obtained from HIV-1-positive individuals when compared with cells obtained from 
patients infected with Mtb only [304, 310]. Of note, the ability of Mtb to arrest 
phagosome-lysosome fusion is maintained in Mtb-HIV-1 co-infected patients [128]. 
It is well established that the architecture of granuloma in co-infected 
individuals is impaired [300, 305]. In addition, comparative in situ cytokine staining 
of granulomas derived from Mtb-infected versus Mtb-HIV-1 co-infected patients 
showed reduced levels of TNF in granulomas from co-infected individuals [305]. 
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There are several factors affecting granuloma containment of Mtb that may lead to 
reactivation of latent TB in HIV-1 co-infected individuals. Firstly, systemic CD4+ T 
cell depletion during HIV-1 infection impairs T cell trafficking into the granuloma 
and destabilizes its organization [316]. Secondly, function of granuloma Mφs is 
affected in the context of cytokine production, e.g. TNF, which results in 
dysproportions between pro- and anti-inflammatory milieu inside granuloma [317]. 
Thirdly, HIV-1 preference to replicate inside activated cells makes granuloma an 
ideal environment for the virus to be produced in T cells and Mφs. This results in an 
increased HIV-1-induced cell death and exhaustion and hence, failure in controlling 
Mtb infection [300]. 
 
 
1.4.2.2 Impact of Mtb on HIV-1 pathogenesis 
 
Mtb infection accelerates the course of HIV-1 infection mainly by 
dysregulation of the immune system. Perturbation of the balance between pro- and 
anti-inflammatory cytokine production, chemokines and impaired apoptosis 
processes account for the dissemination of both pathogens in the co-infected host 
[299, 318]. 
Clinical observations suggested that inflammatory conditions accompanying 
Mtb infection promote replication of HIV-1 [319]. Higher HIV-1 protein levels were 
noted in the BAL fluid from TB-involved lungs compared with uninvolved 
segments, and they were correlated with high TNF concentration [320]. In addition, 
the viral load in BAL fluid was higher than that measured in the plasma, which 
suggested Mtb-infected lungs to be a site of active and extensive viral replication 
[320]. Similar observations were made when viral burden in pleural fluid was 
compared with that in plasma of patients with pleural TB; increased viral loads were 
accompanied by elevated concentrations of pro-inflammatory cytokines in the 
pleural fluid [321]. 
Detailed in vitro studies provided information about the impact of pro-
inflammatory cytokines on activation of HIV-1 LTR. TNF, IL-6 and IL-1β and a direct 
contact between activated lymphocytes and Mφs were found to be responsible for 
enhanced HIV-1 replication [322]. For example, TNF-activated NFκB can bind to 
HIV-1 LTRs and thus enhance transcription of viral proteins [323]. 
Interestingly, not only viral load but also virus heterogeneity is augmented 
both at the site of Mtb infection and systemically in co-infected individuals [324]. In 
HIV-1 samples obtained from dually infected patients frequencies of mutations are 
higher than in virus isolates from HIV-1-infected individuals without active TB 
[325]. Moreover, the spectrum of HIV-1 may be diversified even within one organ. 
This has been shown by Nakata et al. who discovered that viruses isolated from the 
lung segments that harbored Mtb contained a more diverse quasi-species than 
viruses from Mtb-free parts of the lung [320]. 
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DCs infected with Mtb have also been shown to be more efficient in 
mediating HIV trans-infection to T cells than uninfected DCs [326]. Furthermore, we 
recently showed that in the presence of Mtb-infected Mφs DCs increase their HIV 
trans-infecting ability in a bystander fashion, i.e. without coming into direct contact 
with either bacteria or bacteria-infected Mφs (Paper III) [327]. Thus, such an increase 
is merely dependent on the impact of soluble factors released by Mtb-infected Mφs 
[327]. 
The Mtb infection also affects the expression of HIV co-receptors. CCR5 on 
PBMCs from dually infected individuals is overexpressed when compared with cells 
from individuals with HIV infection alone [328]. Furthermore, the mycobacterial cell 
wall compound, ManLAM, induces CCR5 and CXCR4 up-regulation on CD4+ T 
cells in vitro [329]. Interestingly, CXCR4 is also elevated on alveolar Mφs isolated 
from TB patients [330]. Such an alteration has been associated with augmented 
susceptibility of cells to CXCR4-, but not CCR5-using HIV viruses, which suggests 
that concurrent Mtb infection may accelerate progress to AIDS by promoting switch 
from CCR5 to CXCR4 viruses. Finally, a recent study in a mouse model of Mtb 
infection showed that both Ab and cell-mediated responses to HIV Ags, used as a 
potential vaccine, are impaired by a concurrent Mtb infection [331].
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2 THESIS AIMS 
 
 
 
The main goal of this thesis was to examine the interactions between 
Mycobacterium tuberculosis (Mtb) and human immunodeficiency virus type 1 (HIV-1), 
with the special focus on the interplay between these pathogens and the innate 
immune system. 
 
 
 
More specifically the aims of the projects included: 
 
- characterization of glycolipids isolated from the mycobacterial cell wall and 
their effects on dendritic cell maturation and secreted cytokine profiles using 
an in vitro model based on monocyte-derived dendritic cells (paper I); 
 
- studies of Mtb clinical isolates and their ability to infect and induce cytokine 
production in monocyte-derived macrophages (papers II and III); 
 
- investigation of the influence of mycobacteria-infected bystander 
macrophages on the function of dendritic cells, especially in the context of 
maturation and their ability to mediate HIV-1 trans-infection of T cells in an 
in vitro co-infection model (paper III); 
 
- examination of the response of HIV-1-pre-exposed macrophages to 
subsequent Mtb infection; including mechanisms behind impaired cytokine 
response and its correlation with HIV-induced miR-146a expression (paper 
IV).
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3 MATERIALS AND METHODS 
 
 
 
Detailed descriptions of the methods used in the projects are given in the 
respective papers and in the manuscript. Here, descriptions of the methods specific 
for this thesis and non-commercially available reagents are given. 
 
 
 
3.1 MYCOBACTERIAL GLYCOLIPIDS 
 
 
ManLAM and PIMs from the Mtb strain H37Rv or from M. bovis were 
purified using a dry cell wall as a starting material. Such dry cell walls were 
obtained from a large scale mycobacterial culture in the Middlebrook 7H9 medium. 
Dry material was rehydrated in PBS and sonicated. Next, an extraction in 40% 
phenol for 1 h at 70 ºC resulted in obtaining two phases. The water phase was 
dialyzed against water and subjected to affinity chromatography on the 
Concanavalin A-Sepharose column. The retained fraction, the mannose-rich 
material, was eluted and next subjected to hydrophobic interaction chromatography 
on the Phenyl-Sepharose column. After elution the hydrophobic material containing 
aggregated ManLAM and PIMs was subjected to a dissociation step using 0.5% 
sodium deoxycholate for 24 h. Such material was thereafter fractionated by gel 
filtration on a Sephacryl S-100 column in the presence of 0.25% sodium 
deoxycholate. Fractions containing either ManLAM or PIMs were then identified by 
immunodot with the specific mAbs, pooled and dialyzed against water in order to 
remove sodium deoxycholate from the preparations. 
The hydrophobic phase generated during phenol extraction of the cell wall 
was a rich source of PIMs. The hydrophobic phase was washed three times with PBS 
and mixed with an equal volume of 2% SDS in PBS and incubated overnight with a 
constant stirring. Next, the solution was centrifuged and water phase was collected 
and mixed with 9 volumes of ice-cold ethanol. After centrifugation a precipitate was 
obtained and solubilized with 10 mM Tris-HCl, 0.5 M NaCl, 2 mM EDTA and 0.25% 
sodium deoxycholate buffer. The material was then subjected to gel filtration on a 
Sephacryl S-100 column. Fractions containing PIMs were identified by immunodot 
with anti-PIMs mAbs, pooled and dialyzed against water. 
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3.2 MYCOBACTERIAL STRAINS 
 
 
Mycobacterial strains used in the studies are listed in Table 1. 
 
 
 
Table 1. Mycobacterial strains. 
 
Name Species Description Reference 
Included 
in Paper: 
BCG M. bovis BCG 
Attenuated vaccine strain, bacillus 
Calmette-Guerin 
[332] III 
BTB05-552 M. tuberculosis 
Clinical isolate of the Swedish 
outbreak caused by the cluster 
SMI-049, isolated in 2005 
[333] II and III 
BTB05-559 M. tuberculosis 
Clinical isolate of the Swedish 
outbreak caused by the cluster 
SMI-049, isolated in 2005 
[333] II 
H37Rv M. tuberculosis 
Frequently used as reference 
laboratory-adapted Mtb strain, 
first isolated in 1905 
[334, 335] I 
H37Rv-GFP M. tuberculosis 
H37Rv strain expressing green 
fluorescent protein (GFP) 
[336, 337] IV 
Harlingen M. tuberculosis 
Clinical isolate of the tuberculosis 
outbreak in the Netherlands 
[338] III 
M. bovis M. bovis 
Member of Mtb complex, major 
causative agent of bovine 
tuberculosis 
[339] I 
S96-129 M. tuberculosis 
First clinical isolate of the Swedish 
outbreak caused by the cluster 
SMI-049, isolated in 1996 
[333] II and III 
 
 
 
3.3 HIV-1 ISOLATE 
 
 
The primary HIV-1 isolate used in the studies described in papers III and IV 
originated from an asymptomatic patient [340]. This virus had been characterized to 
be CCR5-restricted and since its isolation has been passaged limited number of times 
in the laboratory. 
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3.4 BYSTANDER IN VITRO MODEL 
 
 
In order to study bystander effects of an ongoing Mtb infection on the 
function of DCs an in vitro model was established. It consisted of Mφs pre-infected 
with different mycobacterial strains and of DCs exposed to such Mφs. By the use of 
the semi-permeable membrane, pore size 0.2 µm, separating DCs from Mφs 
investigation of the interplay between DCs and infected Mφs compartments was 
enabled. Such a DCs-Mφs cross-talk was only dependent on the exchange of soluble 
factors released by cells or derived from bacteria, but without possibility for cells or 
entire bacteria to cross the membrane. The model and its in vivo context are depicted 
in Figure 5. 
 
 
 
 
Figure 5. Schematic representation of the in vivo context and the bystander in vitro model. 
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4 RESULTS AND DISCUSSION 
 
 
 
4.1 MYCOBACTERIAL GLYCOLIPIDS AND THEIR INTERACTIONS WITH 
DENDRITIC CELLS (PAPER I) 
 
 
Mannose-capped lipoarabinomannan (ManLAM) and PIMs are glycolipids 
present in the mycobacterial cell wall. Both have been demonstrated to modulate 
immune response to Mtb [7, 110, 122, 199, 208]. However, some discrepancies have 
emerged throughout the years of studying ManLAM as for its ability to influence 
immune cell function. Some groups have reported pro-inflammatory properties of 
ManLAM [194, 341, 342], while others demonstrated an anti-inflammatory activity 
[197, 343-345]. 
In this study we used highly purified ManLAM and PIMs in order to dissect 
their properties and study their abilities to modulate DC function. We found that 
ManLAM was able to trigger production of pro-inflammatory cytokines from human 
monocyte-derived DCs and caused their maturation (Figure 6A-D). Interestingly, 
release of TNF and IL-12p40 by DCs exposed to ManLAM in combination with LPS 
was further potentiated as compared to production triggered by LPS alone (Figure 
6A-B). PIMs on the other hand were not able to activate DCs. Instead, PIMs added 
together with LPS could inhibit production of pro-inflammatory cytokines as 
compared with amounts released upon stimulation with LPS alone (Figure 6A-B). 
The ability of ManLAM to induce IL-12 is especially striking. In our study ManLAM 
alone and in combination with LPS was a potent IL-12p40 inducer (Figure 6B), while 
others reported ManLAM-dependent inhibition of IL-12 released from human DCs 
upon LPS stimulation [197] or, alternatively, that ManLAM was unable to induce   
IL-12p40 production from murine Mφs [346]. Yet, recently another report 
demonstrated that levels of IL-12 produced upon stimulation of DCs with ManLAM 
in combination with LPS were higher than those observed for LPS treatment alone 
[198]. Gringhuis et al. also mentioned, without showing the data however, that 
exposure of cells to ManLAM alone did not result in IL-12 induction [198]. 
Furthermore, in our study, ManLAM triggered up-regulation of DC 
maturation markers, namely CD80, CD86 and MHC class II and co-stimulation of 
DCs with ManLAM and LPS resulted in even higher levels of these markers on DC 
surface. PIMs were not able to activate DCs in this context and DCs exposed to both 
PIMs and LPS displayed less MHC class II molecules than cells exposed to LPS 
alone. 
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Figure 6. Cytokine release by DCs exposed to glycolipids. Normalized levels of (A) TNF, (B) IL-12p40, 
(C) CD86 and (D) MHC class II released during 24 hours upon exposure to ManLAM, PIMs and/or LPS 
at the concentration of 10 µg/ml, 5 µg/ml and 100 ng/ml, respectively. The level of cytokines released 
upon exposure to LPS (100 ng/ml) is shown as 100% of activation (dashed line). Background levels 
(not-treated cells) are 0%. The median percentage change in cytokine production is shown as a line. The 
box defines the 75th and 25th percentiles and the whiskers define the maximum and minimum values 
of 3–9 donors/group. Groups significantly different from LPS-treated control are labeled with asterisks. 
Vertical bars designate significant differences between treatment groups. Wilcoxon matched pair test 
was used to assess statistical significance (* p < 0.05, ** p < 0.01). 
 
Several additional experiments were performed in order to rule out 
contamination of our ManLAM preparation, thus excluding that LPS could be 
responsible for stimulatory effects observed in our study. ManLAM prepared in our 
laboratory was found to be of high quality as demonstrated by silver staining (Figure 
7A) and Western blotting with ManLAM-specific mAbs (Figure 7B). Additionally, 
analysis by capillary electrophoresis with laser-induced fluorescence detection    
(CE-LIF) revealed characteristic for ManLAM sugar content (Figure 7C) and capping 
pattern (Figure 7D). Also, pre-incubation of LPS or ManLAM with ManLAM-specific 
mAbs revealed that observed immuno-stimulatory feature of ManLAM was not LPS-
dependent (Figure 7E). Furthermore, TLR-4 activation triggered by ManLAM was 
much weaker than that mediated by LPS and comparable to that displayed by PIMs 
(Figure 7F). Similarly, endotoxin-like activity observed for ManLAM and LPS in the 
limulus amebocyte lysate (LAL) test could be inhibited by anti-ManLAM mAbs for 
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ManLAM. These mAbs were not inhibitory for LPS, thereby showing that LAL 
positive result for ManLAM was not LPS-derived (data not shown). 
 
 
 
Figure 7. Characterization of ManLAM prepared in our laboratory. (A) ManLAM subjected to SDS-
PAGE followed by staining with periodic acid-silver nitrate method. (B) Western blot analysis of 
ManLAM with a mix of ManLAM-specific and PIM-specific mAbs. CE-LIF analysis of ManLAM-
derived sugars after total (C) and mild (D) acid hydrolysis: A – arabinose, G – glucose, M – mannose, s – 
internal standard (heptose), ManLAM-derived capping mono-, di-, and tri-mannoside oligosaccharides 
are designated as A-M, A-(M)2, and A-(M)3, respectively. (E) TNF release from DCs exposed to 
ManLAM and LPS pre-incubated with ManLAM-specific mAbs. Experiment was carried out in 
triplicates, values are mean +/- SD. Two-tailed, unpaired t-test was used to assess the statistical 
significance (*** p < 0.001). (F) TLR-4-mediated activation of reporter cells exposed to LPS, PIMs and 
ManLAM. 
 
 
In summary, this study demonstrated that two glycolipids derived from the 
mycobacterial cell wall possess divergent immuno-modulatory properties, where 
ManLAM displays pro-inflammatory properties and PIMs are immuno-inhibitory. 
Furthermore, these studies showed that the glycolipids prepared in our laboratory 
were of high purity. Thus, contradictory results obtained by other groups could arise 
from different impurities present in ManLAM preparations. Additionally, conflicting 
reports may also derive from distinct strains used as starting material or even 
different culture conditions. Interestingly, it has been demonstrated that distinct Mtb 
isolates are characterized by specific cell wall composition that in turn may affect the 
immune response against Mtb [347]. Additionally, ManLAM is a heterogeneous 
family of related molecules sharing the same basic structure. Recently, a study 
demonstrated the existence of several isoforms of ManLAM differing by arabinnan 
chain length and number of fatty acids [348]. This was associated with differences in 
ability of those specific ManLAM isoforms to trigger immune response. Possibly, 
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those subtle differences in composition of specific ManLAM preparations may also 
contribute to discrepancies that are noted when investigating ManLAM derived 
from different laboratories. 
 
 
 
4.2 CHARACTERIZATION OF CLINICAL ISOLATES OF 
MYCOBACTERIUM TUBERCULOSIS (PAPERS II AND III)  
 
 
The outbreak of isoniazid-resistant Mtb in Sweden was first reported in 1996. 
The strain that caused this outbreak was characterized and more isolates, collected 
during next years, were annotated to the same group. This group was described as 
cluster SMI-049, based on the RFLP pattern, and by 2010 consisted of 115 isolates 
[333]. 
In the study presented in paper II three isolates of cluster SMI-049 were 
chosen and characterized in detail. Isolate S96-129 was the first to be identified in 
this cluster therefore it is the index isolate. Additionally two isolates obtained nine 
years later and found to go through long chains of transmission between patients 
were included in the study. All three isolates were analyzed by spoligotyping, RFLP 
and massive parallel DNA sequencing. Sequencing revealed that the analyzed strain 
remained genetically very stable despite being present in the population for a long 
period of time and several passages between infected patients. None of the late 
isolates differ extensively from the index case, no large sequence polymorphisms 
were observed. Notably, only a single four amino acid in-frame deletion was found 
in the BTB05-552 isolate and four SNPs in BTB05-559 as compared with the genome 
of the isolate S96-129. Yet, major differences were found when SMI-049 isolates were 
compared with a reference, laboratory H37Rv strain. 
Next, an index case isolate and one of the later isolates (BTB05-552) together 
with a laboratory Mtb strain (H37Rv) were used to infect human monocyte-derived 
Mφs. All tested mycobacterial strains were able to infect and grow inside the Mφs as 
determined by the CFU count in the cell lysate harvested over time (Figure 8A). 
Additionally, Mtb-infected Mφs were counted and the number of bacteria per cell 
assessed after acid fast staining. No significant differences were noted for clinical 
strains and a reference laboratory strain or between isolates. Interestingly, TNF 
release from infected Mφs was found to be similar for all bacteria in the beginning of 
the infection, however, TNF concentrations on day 4 and 6 tended to be higher in 
cultures infected with clinical isolates than with the H37Rv laboratory strain (Figure 
8B). 
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Figure 8. Infection of Mφs with clinical Mtb isolates and a laboratory strain. (A) CFU assessed at the 
different time points for lysates of Mφ infected with isolates of cluster SMI-049 (S96-129 and BTB05-552) 
and a reference Mtb strain (H37Rv). (B) TNF production by Mtb-infected Mφs assayed for different time 
points post-infection. 
 
 
In the next study, described in paper III, we used two clinical isolates of 
cluster SMI-049: S96-129 and BTB05-552. Here, the effects of Mφs infected with Mtb 
on the function of DCs were investigated. In this study we also used another clinical 
isolate, a Harlingen strain, and the avirulent, vaccine strain of Mycobacterium bovis, 
bacillus Calmette-Guerin (BCG). We found that production of pro-inflammatory 
cytokines, namely TNF, IL-12p40 and IL-6, was augmented upon infection with all 
tested strains and the virulent Mtb strains tended to trigger more extensive 
responses than the avirulent BCG strain (Figure 9A-C). 
 
 
 
Figure 9. Cytokine production from co-cultures of DCs and mycobacteria-infected Mφs. Mφs were 
infected with the indicated mycobacteria for 3 h and after that co-cultured with DCs separated from the 
Mφs by a semi-permeable membrane. Concentrations of (A) TNF, (B) IL-12p40 and (C) IL-6 in cell 
culture supernatants were assayed after 48 h of co-culture. Box plots show the median, 25–75% 
interquartile range, and whiskers denoting full range data from n = 9 donors. * p < 0.05, ** p < 0.01 as 
determined by Wilcoxon matched pairs test in relation to non-infected Mφs. 
 
 
Overall, these studies reveal that clinical Mtb isolates of the SMI-049 cluster 
are characterized by genetic stability. Lack of major differences in the isolate 
genomes was paralleled by similar properties tested in the in vitro Mφ model. 
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Importantly, no antibiotic resistance was developed throughout the years when the 
isolates were collected. Similar studies performed on the isolates from Uzbekistan 
and Estonia revealed that mycobacteria belonging to the same lineage may however 
display substantial genomic diversity [349, 350]. The genetic stability of the cluster 
SMI-049, also in the context of stability in the antibiotic susceptibility, was observed 
despite the fact that patients were not diagnosed and treated at the onset of the 
infection. In spite of the low rate of genetic alteration, cluster SMI-049 still 
contributes to one of largest TB outbrakes ever reported for low endemic countries. 
Additionally, the amount of pro-inflammatory cytokines released upon 
infection with cluster SMI049 isolates tended to be augmented when compared with 
the laboratory Mtb strain and avirulent BCG. Of note, it has been demonstrated that 
the amount of TNF produced during TB must be tightly regulated and the outcome 
of the disease depends on this regulation. TNF released in excess causes 
immunopathology in the infected tissue and leads to a general dysregulation of 
immune homeostasis, while deficiency in TNF production has been associated with 
TB reactivation [164, 165]. 
 
 
 
4.3 BYSTANDER EFFECTS OF MYCOBACTERIAL INFECTION ON 
DENDRITIC CELL FUNCTION (PAPER III) 
 
 
In this study we investigated bystander effects that mycobacteria-infected 
Mφs have on the function of DCs. Epidemiological studies have reported that 
progression of the disease caused by either HIV-1 or Mtb is faster in the co-infected 
host [288, 299]. It is known that mycobacterial components can be found systemically 
in Mtb-infected individuals [186, 187, 351]. Furthermore, immunological homeostasis 
of Mtb-infected patients is largely dysregulated [352]. We hypothesized that the 
milieu created during Mtb infection may contribute to altered ability of DCs to 
mediate HIV-1 trans-infection of T cells. 
An in vitro model comprising DCs separated from the mycobacteria-infected 
Mφs by a semi-permeable membrane was set up. It was designed to mimic a 
bystander exposure of DCs to ongoing Mtb infection (see Bystander in vitro model in 
the Material and Methods section, page 35). 
In the co-cultures of DCs and Mφs infected with different mycobacteria 
including avirulent Mycobacterium bovis BCG strain and two virulent clinical isolates 
of Mtb, concentrations of pro-inflammatory cytokines, TNF, IL-12p40 and IL-6, were 
found to be elevated (Figure 9). Similar observations were made when cell-to-cell 
contact between Mφs and DCs was allowed, however, concentrations of the 
cytokines were significantly higher than in the bystander model. In order to check 
which cell type produces which cytokine in the co-cultures we performed several 
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additional experiments: i) mycobacteria-infected Mφs were fixed with 
paraformaldehyde and then added to DCs cultures; ii) DCs were cultured in the 
conditioned medium derived from mycobacteria-infected Mφs and the 
concentrations of the cytokines were compared; iii) cytokines were detected 
intracellularly in co-cultured DCs and Mφs. These experiments led us to the 
conclusion that whereas TNF and IL-6 were produced by both DCs and Mφs,         
IL-12p40 was mainly DC-derived. 
Next, the bystander influence of mycobacteria-infected Mφs on DC 
phenotype was examined. Up-regulation of the CD86 and MHC class II molecules 
was noted on the DCs exposed to Mφs infected with mycobacteria and this effect 
tended to be mycobacterial strain dependent. Levels of MR on DC surface were 
significantly reduced only for Mtb strain S96-129. Interestingly, expression of DC-
SIGN on DCs was unchanged upon exposure to any mycobacteria-infected Mφs. 
Finally, the ability of DCs to infect T cells with HIV-1 in trans was studied. It 
was previously demonstrated that Mtb infection has an enhancing effect on HIV 
infection by increasing virus replication and its genetic heterogeneity [324, 353]. We 
here demonstrated that also ability of DCs to mediate HIV-1 trans-infection of T cells 
is affected by ongoing Mtb infection. We observed a significant increase in DC trans-
infecting ability upon exposure to S96-129, the virulent Mtb strain that exhibited the 
strongest cytokine response from exposed DCs (Figure 10A). Enhanced ability to 
mediate HIV-1 trans-infection was also noted in DC cultures exposed to soluble 
factors released by Mφs infected with another clinical Mtb isolate, BTB05-552 (Figure 
10A). Moreover, in order to analyze which stage of the trans-infection process was 
affected we tested the ability of DC to capture the virus, and found that the virus 
associated better with DCs exposed to Mtb-infection (Figure 10B). In addition, we 
demonstrated that the observed increase in HIV-1 capture and the trans-infection 
ability could be inhibited by mannan, known to block the interaction between DCs 
and C-type lectins [354] (Figure 10A-B). 
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Figure 10. HIV-1 trans-infection and capture ability of Mtb-exposed DCs. (A) Trans-infecting ability of 
DCs cultured in the supernatant derived from Mtb-infected Mφs is presented as p24 levels detected in 
trans-infected PBMC cultures. (B) p24 levels detected in lysates of DCs exposed to soluble factors 
released by Mtb-infected Mφs. Shaded bars represent DCs pre-exposed to mannan in (A) and (B). Data 
are shown as mean + SD from four donors. Statistical significance was assessed by paired t-test. 
Statistical differences between mannan-treated and untreated counterparts are shown above bars 
illustrating mannan-treated cells, and other significances are calculated for group pairs as indicated in 
the graphs and * p < 0.05, ** p < 0.01. 
 
In summary, these studies revealed that soluble factors released by 
mycobacteria-infected Mφs affect several DC functions. Accordingly, we found that 
the pro-inflammatory cytokine production in the DC-infected-Mφs co-cultures was 
increased and accompanied by the partial maturation of DCs. Furthermore, we 
demonstrated that conditions created during Mtb infection potentiated DC-mediated 
trans-infection of T cell with HIV-1. Thus, these studies suggest that Mtb infection 
may create an environment that, in a bystander manner, may promote HIV-1 spread 
and replication in the co-infected individual. 
 
 
 
4.4 MECHANISMS BEHIND IMPAIRED IMMUNE RESPONSE TO MTB IN 
HIV-1 CO-INFECTION SETTING (PAPER IV) 
 
 
It has been demonstrated that control of Mtb infection is deficient in HIV-
infected individuals [288]. HIV-triggered dysregulation of the immune balance has 
been found to contribute to this situation [288]. Indeed, the release of TNF in 
response to Mtb and Mtb-induced apoptosis have been shown to be impaired during 
HIV-1 infection [304, 305, 310]. However, the mechanism responsible for this defect 
is still unknown. 
Here we tested whether the response of human monocyte-derived Mφs to 
Mtb infection is impaired also in regard to production of other cytokines. In fact such 
deficiency was noted not only for TNF but also for IL-10 and IL-6 (Figure 11A-C). 
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This is even more intriguing given the fact that the susceptibility of HIV-exposed 
Mφs to subsequent Mtb infection is augmented together with an increased Mtb 
growth in HIV-exposed cells (our own observations and [314]). Next, the Mtb-
derived glycolipid, mannose-capped lipoarabinomannan (ManLAM), was used to 
stimulate cells and high levels of all cytokines tested were secreted. When Mφs were 
pre-exposed to HIV-1 envelope glycoprotein, gp120, and then treated with ManLAM 
their response to the second stimulus was inhibited in a similar manner as in the 
infection experiment. 
In order to dissect the mechanism of inhibited cytokine response to Mtb 
infection in HIV-infected cells we investigated the expression pattern of miR-146a, a 
miR known to regulate pro-inflammatory responses, in Mφs. Results showed that 
miR-146a was up-regulated, both upon exposure of Mφs to HIV-1 and also to Mtb 
(Figure 11D). Notably, experiments where cytokine release was blocked by brefeldin 
A upon Mtb infection still resulted in miR-146a up-regulation, thus demonstrating 
that induction of this miR was pathogen-specific. Furthermore, cells pre-exposed to 
HIV-1 and then infected with Mtb produced significantly higher levels of miR-146a 
than cells infected with Mtb alone (Figure 11D). In addition, experiments with the 
pathogen compounds, gp120 and ManLAM, suggest that a mere exposure of Mφs to 
HIV-1 gp120 is sufficient to induce miR-146a and to impact the response of the cells 
to a secondary stimulus – in this case mycobacterial ManLAM. 
Figure 11. Cytokine profile and miR-146a expression of Mφs pre-exposed to HIV-1 and infected with 
Mtb. (A-C) Cytokine production and (D) miR-146a expression levels in Mφs infected by either HIV-1, 
Mtb or both pathogens. (D) Fold change of miR-146a expression in relation to U6 gene used as a 
reference was calculated. (A-D) Box plots show the median, 25–75% interquartile range, and whiskers 
denoting full range data from n = 6 independent donors and * p < 0.05 as determined by Wilcoxon 
matched pairs test. 
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In conclusion, we found that HIV-1 is able to trigger up-regulation of       
miR-146a in human Mφs. This was paralleled by an impaired cytokine response of 
such cells to the second pathogen, Mtb. A similar phenomenon was previously 
described for monocytic cells which were anergic to triggering by a secondary TLR 
ligand after LPS stimulation [53-55]. Thus, these findings suggest that HIV-induced 
cross-tolerance in Mφs may contribute to dysregulated responses to Mtb infection in 
co-infected individuals. 
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5 CONCLUDING REMARKS 
 
 
Dysregulation of the immune system is observed in Mtb-HIV-1 co-infected 
individuals. As demonstrated previously, either excessive or limited reaction of the 
immune system to the invading pathogen may lead to disease progression and may 
cause immunopathology [164, 165]. In this thesis the causes of such unbalanced 
immune reactions were investigated. 
First, we demonstrated that mycobacterial cell wall contains glycolipids that 
may display opposite effects on the function of human DCs (paper I). Accordingly, 
ManLAM was found to be immuno-stimulatory, while PIMs were able to inhibit 
pro-inflammatory reactions in DCs, triggered by other stimuli including LPS. These 
observations are of particular importance given the fact that mycobacterial 
glycolipids are found systemically during TB. Thus, their presence may trigger 
reaction of cells located distantly from the site of Mtb infection. Such an influence 
may have a significant impact on the outcome of the infection, in line with the 
observation that the cell wall composition of Mtb relates to the virulence of the 
strains [347]. Indeed, the bystander effects of ongoing Mtb infection were further 
supported by findings described in paper III. Here we found that Mtb-infected Mφs 
influenced DCs without coming into direct contact with them. DCs exposed to Mtb 
infection secreted pro-inflammatory cytokines and underwent partial maturation. 
Moreover, their ability to mediate HIV-1 T cell infection in trans was augmented. 
Additionally, in this study several different mycobacteria were used in order to test 
their distinct impact on in vitro infection outcome. Indeed, we observed strain-
related differences, with avirulent BCG being the least potent inducer of pro-
inflammatory reactions in DCs and Mφs, and clinical isolates triggering stronger 
effects. We did not, however, see a difference between the two Mtb isolates 
belonging to the same cluster, SMI-049, which was identified in the Swedish 
outbreak (paper II). In agreement with similar impact on DC and Mφ immune 
reactions (papers II and III), whole genome sequencing did not reveal any major 
genetic differences between the clinical isolates of cluster SMI-049. Finally, we 
pursued the reason for impaired responsiveness of Mφs to Mtb infection observed 
during co-infection with HIV-1. Here the data suggest that the compromised 
response of HIV-1 pre-exposed Mφs to Mtb infection is associated with up-
regulation of miR-146a, and could be a consequence of HIV-triggered cross-tolerance 
(paper IV). 
Further studies are necessary to gain a full insight into the mechanisms behind 
dysregulated immune responses during Mtb-HIV-1 co-infection. Studies on clinical 
samples from patients would be particularly valuable and could confirm our 
observations from the in vitro models. The approach where the features of infecting 
pathogen are studied and simultaneously related to disease progression (monitored 
in easily accessible patient material, e.g. in blood) would be of a particular 
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importance. In the future, such an approach could lead to better understanding of 
challenges associated with the co-infection and eventually lead to more efficient 
strategies in therapy and hopefully also vaccination. 
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